Zenith Technologies, GE Healthcare Announce Collaboration
News Apr 16, 2016
Zenith Technologies and GE Healthcare’s Life Sciences business have announced a collaboration to support biopharmaceutical manufacturing deployment. As part of the partnership, Zenith Technologies’ methodologies, systems and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.
The two companies will integrate process control systems, manufacturing execution system (MES) solutions and other supporting technologies with GE Healthcare’s start-to-finish technologies and solutions for the biopharmaceutical manufacturing industry. Jan Makela, general manager at BioProcess GE Healthcare said: “The development of our KUBio modular manufacturing facilities and Flex Factory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost.”
“Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies. With Zenith Technologies’ expertise in automation integration and customer support, we will be able to offer more choice to customers.” Brendan O’Regan, founder at Zenith Technologies, said: “This is a significant milestone in our development and ushers in a new era of opportunity for both companies.
“GE offers an unprecedented solution to our pharmaceutical customers to help rapidly deploy capacity and significantly reduce time to market. Combined with our manufacturing software systems and on the ground, global support services, we can help biopharmaceutical manufacturers improve their processes and ultimately increase their competitiveness.”
Headquartered in Cork and with 14 offices globally, Zenith Technologies delivers manufacturing software systems that enable life science businesses to be compliant and competitive. The company combines pharmaceutical industry expertise and full life-cycle support, including managed services, with a portfolio of technology application and platform experience.
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018